Skip to main content

Table 1 Baseline characteristics of included studies

From: Design, analysis, and reporting of pilot studies in HIV: a systematic review and methodological study

Characteristics

Statistic (n = 248)

Design, n (%)

 Randomized control trial

108 (43.5)

 Non-randomized trial

140 (56.5)

Intervention type, n (%)

 Pharmaceutical

21 (8.5)

 Non-pharmaceutical

227 (91.5)

Number of study sites, n (%)

 Single site

143 (57.7)

 Multiple sites

105 (42.3)

Region, n (%)

 Africa

71 (28.6)

 Americas

137 (55.2)

 Southeast Asia

11 (4.4)

 Europe

16 (6.5)

 Western Pacific

8 (3.2)

 Mixed region

5 (2)

Country income level, n (%)a

 High income

151 (60.9)

 Upper-middle income

37 (14.9)

 Lower-middle income

25 (10.1)

 Low income

33 (13.3)

 Mixed income

2 (0.8)

Qualitative methods, n (%)

75 (30.2)

Sample size: median (min, max)

40 (3, 8794)

Key population, n (%)

 Contain any key population

134 (54)

Specific key populations, n (%)

 Injection drug User

4 (1.6)

 MSM

20 (8.1)

 Incarcerated populations

0 (0)

 Commercial sex workers

1 (0.4)

 Pregnant women

11 (4.4)

 Children

5 (2)

 Youth

28 (11.3)

 Indigenous

0 (0)

 African, Caribbean, Black

77 (31)

 Women

24 (9.1)

 Transgender

3 (1.2)

Progression criteria prespecified, n (%)

5 (2)

Trial outcome, n (%)

 Proceed to larger study

65 (26.2)

 Do not proceed

183 (73.8)